The metabolic syndrome in patients with chronic obstructive pulmonary disease.

PURPOSE This study was undertaken to evaluate the presence of the metabolic syndrome in COPD patients who participated in a cardiopulmonary rehabilitation program. The metabolic syndrome is characterized by the presence of abdominal obesity, atherogenic dyslipidemia, raised blood pressure, presence of insulin resistance, and prothrombotic and inflammatory states that predispose to cardiovascular diseases. METHODS Thirty-eight COPD patients (age: 66 +/- 7 years, [mean +/- SD], FEV1: 43 +/- 16% predicted) and 34 control participants matched for age and gender are included in this study. The criteria for the identification of the metabolic syndrome include 3 or more of the following features: abdominal obesity (waist circumference: > 102 cm in men, > 88 cm in women), triglycerides levels (>or= 1.69 mmol/L), high-density lipoprotein cholesterol levels (< 1.0 mmol/L in men, < 1.3 mmol/L in women), blood pressure (>or= 130/ >or= 85 mm Hg), and fasting glucose levels (>or= 6.1 mmol/L). RESULTS Forty-seven percent of COPD patients and 21% of control participants presented 3 or more determinants of the metabolic syndrome. CONCLUSIONS The presence of metabolic syndrome is frequent in patients with COPD who participated in a cardiopulmonary program. Hence, this population should be considered for screening for the metabolic syndrome.

[1]  Cranford L Scott,et al.  Diagnosis, prevention, and intervention for the metabolic syndrome. , 2003, The American journal of cardiology.

[2]  J. Després,et al.  Waist circumference, visceral obesity, and cardiovascular risk. , 2003, Journal of cardiopulmonary rehabilitation.

[3]  Don D. Sin,et al.  Why Are Patients With Chronic Obstructive Pulmonary Disease at Increased Risk of Cardiovascular Diseases?: The Potential Role of Systemic Inflammation in Chronic Obstructive Pulmonary Disease , 2003 .

[4]  Shankuan Zhu,et al.  The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988-1994. , 2003, Archives of internal medicine.

[5]  R. Ross,et al.  Discrimination of health risk by combined body mass index and waist circumference. , 2003, Obesity research.

[6]  Jukka T Salonen,et al.  The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. , 2002, JAMA.

[7]  B. Hedblad,et al.  Lung Function and Cardiovascular Risk: Relationship With Inflammation-Sensitive Plasma Proteins , 2002, Circulation.

[8]  Y. Lacasse,et al.  Midthigh muscle cross-sectional area is a better predictor of mortality than body mass index in patients with chronic obstructive pulmonary disease. , 2002, American journal of respiratory and critical care medicine.

[9]  W. Dietz,et al.  Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. , 2002, JAMA.

[10]  L. Groop,et al.  Cardiovascular morbidity and mortality associated with the metabolic syndrome. , 2001, Diabetes care.

[11]  M. Trevisan,et al.  Syndrome X and mortality: a population-based study. Risk Factor and Life Expectancy Research Group. , 1998, American journal of epidemiology.

[12]  D. Redelmeier,et al.  The treatment of unrelated disorders in patients with chronic medical diseases. , 1998, The New England journal of medicine.

[13]  S. Haffner,et al.  Development of the multiple metabolic syndrome: an epidemiologic perspective. , 1998, Epidemiologic reviews.

[14]  V M Hawthorne,et al.  Impaired lung function and mortality risk in men and women: findings from the Renfrew and Paisley prospective population study , 1996, BMJ.

[15]  O. Yavuz,et al.  The effect of high-dose inhaled budesonide on lipid profile in asthmatic patients. , 1996, General pharmacology.

[16]  B. Morgenstern,et al.  Human blood pressure determination by sphygmomanometry. , 1993, Circulation.

[17]  S. Haffner,et al.  Prospective Analysis of The Insulin-Resistance Syndrome (Syndrome X) , 1992, Diabetes.

[18]  M. Hartog,et al.  Plasma and Lipoprotein Lipids and Apolipoproteins AI, AII and B in Patients with Chronic Airflow Limitation , 1989, Journal of the Royal Society of Medicine.

[19]  G. Reaven.  Role of Insulin Resistance in Human Disease , 1988, Diabetes.

[20]  S. Grundy,et al.  Increased high density lipoprotein cholesterol in obstructive pulmonary disease (predominant emphysematous type). , 1981, Metabolism: clinical and experimental.

[21]  A. Siegelaub,et al.  Lung function and risk of myocardial infarction and sudden cardiac death. , 1976, The New England journal of medicine.

[22]  R. Levy,et al.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. , 1972, Clinical chemistry.